scispace - formally typeset
Journal ArticleDOI

Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

Reads0
Chats0
TLDR
The results demonstrate the saturable transfer of L‐KYN across the blood–brain barrier and suggest that circulating L‐ KYN, 3‐HKYN, and ANA may each contribute significantly to respective cerebral pools under normal conditions.
Abstract
To evaluate the potential contribution of circulating kynurenines to brain kynurenine pools, the rates of cerebral uptake and mechanisms of blood-brain barrier transport were determined for several kynurenine metabolites of tryptophan, including L-kynurenine (L-KYN), 3-hydroxykynurenine (3-HKYN), 3-hydroxyanthranilic acid (3-HANA), anthranilic acid (ANA), kynurenic acid (KYNA), and quinolinic acid (QUIN), in pentobarbital-anesthetized rats using an in situ brain perfusion technique. L-KYN was found to be taken up into brain at a significant rate [permeability-surface area product (PA) = 2-3 x 10(-3) ml/s/g] by the large neutral amino acid carrier (L-system) of the blood-brain barrier. Best-fit estimates of the Vmax and Km of saturable L-KYN transfer equalled 4.5 x 10(-4) mumol/s/g and 0.16 mumol/ml, respectively. The same carrier may also mediate the brain uptake of 3-HKYN as D,L-3-HKYN competitively inhibited the brain transfer of the large neutral amino acid L-leucine. For the other metabolites, uptake appeared mediated by passive diffusion. This occurred at a significant rate for ANA (PA, 0.7-1.6 x 10(-3) ml/s/g), and at far lower rates (PA, 2-7 x 10(-5) ml/s/g) for 3-HANA, KYNA, and QUIN. Transfer for KYNA, 3-HANA, and ANA also appeared to be limited by plasma protein binding. The results demonstrate the saturable transfer of L-KYN across the blood-brain barrier and suggest that circulating L-KYN, 3-HKYN, and ANA may each contribute significantly to respective cerebral pools. In contrast, QUIN, KYNA, and 3-HANA cross the blood-brain barrier poorly, and therefore are not expected to contribute significantly to brain pools under normal conditions.

read more

Citations
More filters
Journal ArticleDOI

Kynurenines in the mammalian brain: when physiology meets pathology

TL;DR: With recently developed pharmacological agents, it is now possible to restore metabolic equilibrium and envisage novel therapeutic interventions on the basis of the kynurenine pathway.
Journal ArticleDOI

Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice

TL;DR: Results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.
Journal ArticleDOI

A Meta-Analysis of Cytokines in Alzheimer's Disease

TL;DR: The results strengthen the clinical evidence that AD is accompanied by an inflammatory response, particularly higher peripheral concentrations of IL-6, TNF-α, IL-1β, TGF-β,IL-12 and IL-18 and higher CSF concentrations of T GF-β.
Journal ArticleDOI

Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications

TL;DR: This review explores the idea that specific gene polymorphisms and neurotransmitter systems can confer protection from or vulnerability to specific symptom dimensions of cytokine-related depression and potential therapeutic strategies that target inflammatory cytokine signaling.
Journal ArticleDOI

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

TL;DR: It is concluded that inflammatory diseases are associated with accumulation of QUIN, kynurenic acid and L-kynurenine within the central nervous system, but that the available data do not support a role for QUIN in the aetiology of Huntington's disease or Alzheimer's disease.
References
More filters
Journal ArticleDOI

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims

TL;DR: The Huntington disease brain has a disproportionately high capability to produce the endogenous "excitotoxin" quinolinic acid according to the activity of 3-hydroxyanthranilate oxygenase.
Journal ArticleDOI

SYNTHESIS AND METABOLISM OF l‐KYNURENINE IN RAT BRAIN

TL;DR: Kynurenine was formed from tryptophan in brain and was also taken up from the periphery, and kynuramine levels in different areas of the brain were similar to those of tryptamine.
Book ChapterDOI

In Vivo Measurement of Brain Serotonin Turnover

TL;DR: The development of techniques to estimate the turnover of 5-HT in vivo will allow studying the effects of environmental change and drugs on indole metabolism in the brain and to acquire a better understanding of the fundamental role of5-HT.
Journal ArticleDOI

Kynurenines and seizures.

I. P. Lapin
- 01 Jun 1981 - 
TL;DR: The involvement of brain kynurenines in the genesis of epileptic seizures is suggested and derivatives of GABA and some standard anticonvulsant drugs alter seizures induced by l‐kynurenine and quinolinic acid in different ways.
Journal ArticleDOI

The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain.

TL;DR: The presence of quinolinic acid (2,3-pyridinedicarboxylic acid, QA) in the rat brain has been demonstrated using a mass-spectrometric method and support the idea that QA merits special attention as a potential transmitter and as an endogenous excitotoxin in brain.
Related Papers (5)